Recent phase II clinical trials have shown that AZD1775 enhances the efficacy of carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to platinum-based first-line therapy31. The gene discussed is TP53; the disease is ovarian carcinoma.